Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe

This study has been completed.
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00314522
First received: April 11, 2006
Last updated: February 23, 2016
Last verified: December 2011
  Purpose
This study performed a retrospective analysis of patient images to develop software in determining dose delivered for each fraction treatment.

Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 5
Study Start Date: September 2005
Estimated Study Completion Date: March 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clniic
Criteria

Inclusion Criteria:

  • Subject 18 years of age and over
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00314522

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00314522     History of Changes
Other Study ID Numbers: EX-0003 
Study First Received: April 11, 2006
Last Updated: February 23, 2016
Health Authority: Canada: Health Canada

ClinicalTrials.gov processed this record on April 27, 2016